RankingsPricing
  1. US-listed companies
  2. PharmaCyte Biotech, Inc.

PharmaCyte Biotech, Inc.PMCB

Market cap
$16.94M
P/E ratio
Back to summarized table
Income statementBalance sheetCash flow
Apr 30,
2012		Apr 30,
2013		Apr 30,
2014		Apr 30,
2015		Apr 30,
2016		Apr 30,
2017		Apr 30,
2018		Apr 30,
2019		Apr 30,
2020		Apr 30,
2021		Apr 30,
2022		Apr 30,
2023
Cash and cash equivalents15,723199,303---------68
Prepaid expenses and other current assets-127,870570,106119,257110,02674,274224,067138,151142,78573,13194,172107,681
Total current assets1243241653,404128568
Intangible assets-----------4
Investment in SG Austria--2222222222
Other assets----------7,6887,688
Total other assets---555555555
Total Assets23987966679173
Accounts payable730,068351,996188,044496,699336,009365,600352,621121,885185,842172,261205,361128,281
Accrued expenses407,46312,3007,80323,667151,630214,648291,547620,966816,638552,517499,009458,300
Total current liabilities44373,6662637,639580,248644,168742,8511724,778704,370586,581
Total Liabilities44373,6662637,639580,248644,168742,8511724,778704,370586,581
Common stock, authorized: 133,333,334 shares, $0.0001 par value; shares issued 21,602,078, shares outstanding 16,793,980 as of April 30, 2023, and 20,721,047 shares issued and outstanding as of April 30, 202241,63148,21169,06373,27378,12790,534101,326118,600163,8641592,0722,160
Additional paid-in capital384076859197102105109114202202
Accumulated deficit-39,848,005-41,446,107-68,700,127-79,554,636-84,691,617-89,135,302-95,964,143-100,031,371-103,858,259-107,409,495-111,648,656-115,958,773
Treasury stock, at cost, 4,808,098 and 0 shares as of April 30, 2023, and 2022, respectively-----------14
Accumulated other comprehensive loss---1,4628061,736-4,709-13,842-21,709-20,382-15,757-23,003
Total stockholders' equity-2,279,850-1,501,456967865579073
Total Liabilities and Stockholders' Equity23987966679173